

# Li Auto Inc. (LI US)

## Is the *Mega* lesson worthwhile?

We are of the view that Li Auto has lowered priority for its FY24E profitability and the sell-off after the 1Q24 earnings call has largely priced in such management mentality. We believe the key lies in its new BEV strategy, EREV sales recovery in 2H24 and FY25 sales growth with BEVs being postponed.

■ **1Q24 GP in line; R&D and SG&A dragged NP.** Li Auto's 1Q24 revenue was about 3% higher than our prior forecast, largely due to its other sales and services. GP was 1% higher than our projection. On the other hand, R&D and SG&A combined exceeded our estimates by RMB1.6bn. Accordingly, 1Q24 NP was about RMB1.4bn lower than our forecast.

■ **2Q24 and FY24E outlook.** Management expects 2Q24 to be challenging and guides vehicle gross margin at 18% (vs. 19.3% in 1Q24). R&D and SG&A in 2Q24 could be even more difficult to forecast, as its recent organizational restructuring may involve some one-off expenses. We cut FY24E R&D by RMB1.5bn to 8.9% of revenue and SG&A by RMB0.8bn to 8.8% of revenue. Both ratios are higher than those in FY23. Despite its cost reduction efforts, the automaker is still determined to increase its fast-charging network and optimize its store number and size.

We cut our FY24E sales volume by 22% to 0.51mn units, as the automaker has postponed its BEV SUV launches to FY25 and the *Mega* sales volume was way below expectation. We also cut GPM by 0.8ppt to 20.1%. Therefore, we halve our FY24E NP estimate to RMB7.2bn.

■ ***Mega* has pushed Li Auto to refine its BEV strategy.** It appears to us that the company has lowered its priority for FY24E profitability but has been focusing on laying a more solid foundation for BEV's success after the wrong expectation on the *Mega*. We believe such failure does not mean the company has lost its superb product design capabilities. We project FY25E sales volume to be 0.66mn units and NP to be RMB12.3bn (both are at similar levels as our prior forecasts for FY24E).

■ **Valuation/Key risks.** We maintain our BUY rating but trim our target price from US\$48.00 to US\$26.00, based on 15x our revised FY25 EPS (prior 23x FY24 EPS). We roll over our valuation multiple to FY25, as we believe well-thought-out BEV products could help Li Auto regain traction. We lower our valuation multiple to reflect higher uncertainties and lower profit growth trajectory. Key risks to our rating and target price include lower sales and/or gross margin than our expectation, as well as a sector de-rating.

### Earnings Summary

(YE 31 Dec)	FY22A	FY23A	FY24E	FY25E	FY26E
Revenue (RMB mn)	45,287	123,851	149,240	193,270	234,100
YoY growth (%)	67.7	173.5	20.5	29.5	21.1
Gross margin (%)	19.4	22.2	20.1	20.3	20.3
Operating profit (RMB mn)	(3,654.9)	7,142.7	3,561.5	8,919.6	14,309.3
Net profit (RMB mn)	(2,012.2)	11,704.1	7,227.8	12,268.1	17,325.9
YoY growth (%)	na	na	(38.2)	69.7	41.2
Adjusted net profit (RMB mn)	41.0	12,092.6	8,940.4	13,522.3	18,567.1
EPS (Reported) (RMB)	(1.04)	5.95	3.62	6.09	8.51
P/S (x)	3.7	1.3	1.1	0.9	0.7
P/E (x)	ns	13.2	21.7	12.9	9.2
P/B (x)	3.4	2.6	2.3	1.9	1.6

Source: Company data, Bloomberg, CMBIGM estimates

## BUY (Maintain)

**Target Price** US\$26.00

(Previous TP) US\$48.00

**Up/Downside** 19.8%

**Current Price** US\$21.71

### China Auto

#### Ji SHI, CFA

(852) 3761 8728

shiji@cmbi.com.hk

#### Wenjing DOU, CFA

(852) 6939 4751

douwenjing@cmbi.com.hk

### Stock Data

Mkt Cap (US\$ mn)	23,034.5
Avg 3 mths t/o (US\$ mn)	170.4
52w High/Low (US\$)	46.65/21.71
Total Issued Shares (mn)	2122.0

Source: FactSet

### Shareholding Structure

Mr. Li Xiang	21.9%
Mr. Wang Xing	17.9%


Source: NASDAQ

### Share Performance

	Absolute	Relative
1-mth	-17.7%	-31.0%
3-mth	-34.5%	-45.0%
6-mth	-46.8%	-51.8%

Source: FactSet

### 12-mth Price Performance



Source: FactSet

### Related Report

["Li Auto Inc. \(LI US\) - 4Q23 results set the tone for resilient FY24" - 27 Feb 2024](#)

Figure 1: Quarterly results

RMB mn	1Q23	2Q23	3Q23	4Q23	1Q24	YoY	QoQ
Sales volume (units)	52,584	86,533	105,108	131,805	80,400	52.9%	-39.0%
ASP (RMB)	357,277	331,119	329,941	316,620	318,827	-10.8%	0.7%
Revenue	18,787	28,653	34,679	41,732	25,634	36.4%	-38.6%
Gross profit	3,830	6,235	7,644	9,787	5,284	38.0%	-46.0%
R&D expenses	(1,852)	(2,426)	(2,817)	(3,491)	(3,049)	64.6%	-12.7%
SG&A expenses	(1,645)	(2,309)	(2,544)	(3,270)	(2,978)	81.0%	-8.9%
Operating profit	405	1,626	2,339	3,036	(585)	N/A	N/A
Net profit	930	2,293	2,823	5,658	593	-36.3%	-89.5%
Gross margin	20.4%	21.8%	22.0%	23.5%	20.6%	0.2 ppt	-2.8 ppt
Operating margin	2.2%	5.7%	6.7%	7.3%	-2.3%	-4.4 ppt	-9.6 ppt
Net margin	4.9%	8.0%	8.1%	13.6%	2.3%	-2.6 ppt	-11.2 ppt

Source: Company data, CMBIGM

Figure 2: Earnings revision

RMB mn	New			Old			Diff (%)		
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	149,240	193,270	234,100	201,900	263,000	N/A	-26.1%	-26.5%	N/A
Gross profit	29,952	39,210	47,580	42,472	53,933	N/A	-29.5%	-27.3%	N/A
Operating profit	4,061	9,620	15,109	13,648	17,960	N/A	-70.2%	-46.4%	N/A
Net profit	7,228	12,268	17,326	14,502	18,619	N/A	-50.2%	-34.1%	N/A
Gross margin	20.1%	20.3%	20.3%	21.0%	20.5%	N/A	-1.0 ppt	-0.2 ppt	N/A
Operating margin	2.7%	5.0%	6.5%	6.8%	6.8%	N/A	-4.0 ppt	-1.9 ppt	N/A
Net margin	4.8%	6.3%	7.4%	7.2%	7.1%	N/A	-2.3 ppt	-0.7 ppt	N/A

Source: CMBIGM estimates

Figure 3: CMBI estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	149,240	193,270	234,100	187,562	251,659	312,571	-20.4%	-23.2%	-25.1%
Gross profit	29,952	39,210	47,580	39,062	52,909	66,421	-23.3%	-25.9%	-28.4%
Operating profit	4,061	9,620	15,109	11,109	18,206	23,730	-63.4%	-47.2%	-36.3%
Net profit	7,228	12,268	17,326	15,040	22,559	27,987	-51.9%	-45.6%	-38.1%
Gross margin	20.1%	20.3%	20.3%	20.8%	21.0%	21.2%	-0.8 ppt	-0.7 ppt	-0.9 ppt
Operating margin	2.7%	5.0%	6.5%	5.9%	7.2%	7.6%	-3.2 ppt	-2.3 ppt	-1.1 ppt
Net margin	4.8%	6.3%	7.4%	8.0%	9.0%	9.0%	-3.2 ppt	-2.6 ppt	-1.6 ppt

Source: Bloomberg, CMBIGM estimates

## Financial Summary

INCOME STATEMENT	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
<b>Revenue</b>	<b>27,010</b>	<b>45,287</b>	<b>123,851</b>	<b>149,240</b>	<b>193,270</b>	<b>234,100</b>
Cost of goods sold	(21,248)	(36,496)	(96,355)	(119,288)	(154,060)	(186,520)
<b>Gross profit</b>	<b>5,761</b>	<b>8,790</b>	<b>27,497</b>	<b>29,952</b>	<b>39,210</b>	<b>47,580</b>
<b>Operating expenses</b>	<b>(6,779)</b>	<b>(12,445)</b>	<b>(20,354)</b>	<b>(26,391)</b>	<b>(30,290)</b>	<b>(33,271)</b>
SG&A expense	(3,492)	(5,665)	(9,768)	(13,165)	(15,089)	(16,495)
R&D expense	(3,286)	(6,780)	(10,586)	(13,226)	(15,201)	(16,776)
<b>Operating profit</b>	<b>(1,017)</b>	<b>(3,655)</b>	<b>7,143</b>	<b>3,561</b>	<b>8,920</b>	<b>14,309</b>
Gain/loss on financial assets at FVTPL	0	0	0	0	0	0
Investment gain/loss	527	376	783	1,400	1,737	2,232
Other gains/(losses)	187	626	1,048	915	1,020	1,020
<b>EBITDA</b>	<b>501</b>	<b>(839)</b>	<b>12,343</b>	<b>11,282</b>	<b>18,846</b>	<b>26,828</b>
Depreciation	590	1,214	1,805	2,953	4,679	6,399
<b>EBIT</b>	<b>(90)</b>	<b>(2,053)</b>	<b>10,538</b>	<b>8,328</b>	<b>14,167</b>	<b>20,429</b>
Interest income	213	600	1,300	1,952	1,790	2,067
Interest expense	(63)	(106)	(86)	(69)	(56)	(50)
<b>Pre-tax profit</b>	<b>(153)</b>	<b>(2,159)</b>	<b>10,452</b>	<b>8,259</b>	<b>14,111</b>	<b>20,379</b>
Income tax	(169)	127	1,357	(991)	(1,693)	(2,853)
<b>After tax profit</b>	<b>(321)</b>	<b>(2,032)</b>	<b>11,809</b>	<b>7,268</b>	<b>12,418</b>	<b>17,526</b>
Minority interest	0	20	(105)	(40)	(150)	(200)
Discontinued operations	0	0	0	0	0	0
Others	0	0	0	0	0	0
<b>Net profit</b>	<b>(321)</b>	<b>(2,012)</b>	<b>11,704</b>	<b>7,228</b>	<b>12,268</b>	<b>17,326</b>
<b>Adjusted net profit</b>	<b>780</b>	<b>41</b>	<b>12,093</b>	<b>8,940</b>	<b>13,522</b>	<b>18,567</b>

BALANCE SHEET	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
<b>Current assets</b>	<b>52,380</b>	<b>66,992</b>	<b>114,526</b>	<b>129,162</b>	<b>158,556</b>	<b>194,407</b>
Cash & equivalents	27,854	38,478	91,329	85,582	92,440	113,302
Restricted cash	2,639	1,940	0	500	500	500
Account receivables	121	48	144	245	265	385
Inventories	1,618	6,805	6,872	8,170	10,552	12,775
ST bank deposits	19,668	18,031	11,933	30,933	50,933	63,933
Other current assets	481	1,690	4,247	3,731	3,865	3,512
<b>Non-current assets</b>	<b>9,468</b>	<b>19,545</b>	<b>28,942</b>	<b>43,321</b>	<b>50,848</b>	<b>59,226</b>
PP&E	4,498	11,188	15,745	23,804	31,134	36,743
Right-of-use assets	2,061	3,539	5,939	11,159	9,378	10,709
Deferred income tax	20	75	1,990	1,200	1,500	1,500
Investment in JVs & assos	156	1,484	1,595	2,510	3,030	3,400
Intangibles	751	833	864	911	968	1,016
Other non-current assets	1,981	2,427	2,808	3,736	4,837	5,858
<b>Total assets</b>	<b>61,849</b>	<b>86,538</b>	<b>143,467</b>	<b>172,483</b>	<b>209,403</b>	<b>253,633</b>
<b>Current liabilities</b>	<b>12,108</b>	<b>27,373</b>	<b>72,743</b>	<b>81,623</b>	<b>103,931</b>	<b>126,271</b>
Short-term borrowings	0	0	688	0	0	0
Account payables	9,376	20,024	51,870	65,363	84,416	102,203
Other current liabilities	2,259	6,652	19,038	13,783	17,444	21,677
Lease liabilities	473	696	1,146	2,477	2,070	2,391
<b>Non-current liabilities</b>	<b>8,676</b>	<b>13,979</b>	<b>10,150</b>	<b>21,292</b>	<b>22,217</b>	<b>25,323</b>
Long-term borrowings	563	3,317	1,747	1,513	1,713	1,713
Convertible bonds	5,398	5,914	0	6,032	6,032	6,032
Obligations under finance leases	0	0	0	0	0	0
Deferred income	390	582	812	1,535	2,312	3,253
Other non-current liabilities	2,326	4,167	7,590	12,213	12,160	14,326
<b>Total liabilities</b>	<b>20,785</b>	<b>41,352</b>	<b>82,892</b>	<b>102,915</b>	<b>126,147</b>	<b>151,594</b>
Share capital	1	1	1	1	1	1
Capital surplus	49,390	53,869	57,480	59,205	60,475	61,732
Retained earnings	(8,328)	(9,012)	2,661	9,889	22,157	39,483
Other reserves	(0)	(0)	(0)	(0)	(0)	(0)
<b>Total shareholders equity</b>	<b>41,064</b>	<b>44,859</b>	<b>60,143</b>	<b>69,096</b>	<b>82,633</b>	<b>101,216</b>
<b>Total equity and liabilities</b>	<b>61,849</b>	<b>86,210</b>	<b>143,035</b>	<b>172,011</b>	<b>208,781</b>	<b>252,810</b>

<b>CASH FLOW</b>	<b>2021A</b>	<b>2022A</b>	<b>2023A</b>	<b>2024E</b>	<b>2025E</b>	<b>2026E</b>
<b>YE 31 Dec (RMB mn)</b>						
<b>Operating</b>						
Profit before taxation	(153)	(2,159)	10,452	8,259	14,111	20,379
Depreciation & amortization	590	1,214	1,805	2,953	4,679	6,399
Change in working capital	6,565	5,035	36,612	13,203	21,650	21,073
Others	1,338	3,290	1,825	1,318	(609)	(1,454)
<b>Net cash from operations</b>	<b>8,340</b>	<b>7,380</b>	<b>50,694</b>	<b>25,733</b>	<b>39,832</b>	<b>46,397</b>
<b>Investing</b>						
Capital expenditure	(3,445)	(5,128)	(6,507)	(11,080)	(12,100)	(12,100)
Acquisition of subsidiaries/ investments	(631)	(762)	(198)	(400)	(400)	(300)
Net proceeds from disposal of short-term investments	(504)	1,686	16,316	(9,000)	(8,000)	(8,000)
Others	323	(161)	(9,622)	(10,000)	(12,000)	(5,000)
<b>Net cash from investing</b>	<b>(4,257)</b>	<b>(4,365)</b>	<b>(12)</b>	<b>(30,480)</b>	<b>(32,500)</b>	<b>(25,400)</b>
<b>Financing</b>						
Net borrowings	170	3,080	(1,001)	(513)	(490)	(150)
Proceeds from share issues	11,006	2,469	1,186	13	15	15
Others	5,533	90	0	0	0	0
<b>Net cash from financing</b>	<b>16,710</b>	<b>5,639</b>	<b>185</b>	<b>(501)</b>	<b>(474)</b>	<b>(135)</b>
<b>Net change in cash</b>						
Cash at the beginning of the year	10,173	30,493	40,418	91,330	86,082	92,940
Exchange difference	(472)	1,270	45	0	0	0
Others	0	0	0	0	0	0
<b>Cash at the end of the year</b>	<b>30,493</b>	<b>40,418</b>	<b>91,330</b>	<b>86,082</b>	<b>92,940</b>	<b>113,802</b>
<b>GROWTH</b>	<b>2021A</b>	<b>2022A</b>	<b>2023A</b>	<b>2024E</b>	<b>2025E</b>	<b>2026E</b>
<b>YE 31 Dec</b>						
Revenue	185.6%	67.7%	173.5%	20.5%	29.5%	21.1%
Gross profit	271.9%	52.6%	212.8%	8.9%	30.9%	21.3%
Operating profit	na	na	na	(50.1%)	150.4%	60.4%
EBITDA	151.6%	na	na	(8.6%)	67.1%	42.4%
EBIT	na	na	na	(21.0%)	70.1%	44.2%
Net profit	na	na	na	(38.2%)	69.7%	41.2%
Adj. net profit	na	(94.7%)	29,430.1%	(26.1%)	51.2%	37.3%
<b>PROFITABILITY</b>	<b>2021A</b>	<b>2022A</b>	<b>2023A</b>	<b>2024E</b>	<b>2025E</b>	<b>2026E</b>
<b>YE 31 Dec</b>						
Gross profit margin	21.3%	19.4%	22.2%	20.1%	20.3%	20.3%
Operating margin	(3.8%)	(8.1%)	5.8%	2.4%	4.6%	6.1%
EBITDA margin	1.9%	(1.9%)	10.0%	7.6%	9.8%	11.5%
Adj. net profit margin	2.9%	0.1%	9.8%	6.0%	7.0%	7.9%
Return on equity (ROE)	(0.9%)	(4.7%)	22.3%	11.2%	16.2%	18.8%
<b>GEARING/LIQUIDITY/ACTIVITIES</b>	<b>2021A</b>	<b>2022A</b>	<b>2023A</b>	<b>2024E</b>	<b>2025E</b>	<b>2026E</b>
<b>YE 31 Dec</b>						
Current ratio (x)	4.3	2.4	1.6	1.6	1.5	1.5
Receivable turnover days	1.6	0.4	0.4	0.6	0.5	0.6
Inventory turnover days	27.8	68.1	26.0	25.0	25.0	25.0
Payable turnover days	161.1	200.3	196.5	200.0	200.0	200.0
<b>VALUATION</b>	<b>2021A</b>	<b>2022A</b>	<b>2023A</b>	<b>2024E</b>	<b>2025E</b>	<b>2026E</b>
<b>YE 31 Dec</b>						
P/E	ns	ns	13.2	21.7	12.9	9.2
P/E (diluted)	ns	ns	14.2	21.7	12.9	9.2
P/B	3.5	3.4	2.6	2.3	1.9	1.6
P/CFPS	17.4	20.6	3.0	6.1	4.0	3.4
Div yield (%)	0.0	0.0	0.0	0.0	0.0	0.0

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

# Disclosures & Disclaimers

## Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

## CMBIGM Ratings

**BUY** : Stock with potential return of over 15% over next 12 months  
**HOLD** : Stock with potential return of +15% to -10% over next 12 months  
**SELL** : Stock with potential loss of over 10% over next 12 months  
**NOT RATED** : Stock is not rated by CMBIGM

**OUTPERFORM** : Industry expected to outperform the relevant broad market benchmark over next 12 months  
**MARKET-PERFORM** : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months  
**UNDERPERFORM** : Industry expected to underperform the relevant broad market benchmark over next 12 months

## CMB International Global Markets Limited

**Address:** 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

**CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)**

## Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

### For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

### For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.